This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Institut Jean Paoli & Irène Calmettes, National Institute of Health and Medical Research. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 5,383 
1 out of 32 
1 out of 1,853 
Years Active: 2018
Title: Julie Gertner-Dardenne: Innovator in Therapeutic Antagonists
Introduction
Julie Gertner-Dardenne is a prominent inventor based in Valbonne-Sophia Antipolis, France. She has made significant contributions to the field of therapy through her innovative research and development. Her work focuses on the interaction between BTLA and HVEM, which has implications for therapeutic applications.
Latest Patents
Julie holds a patent titled "Antagonist of the BTLA/HVEM interaction for use in therapy." This invention relates to an antagonist that increases the proliferation of Vγ9Vδ2 T cells, showcasing her commitment to advancing therapeutic options.
Career Highlights
Throughout her career, Julie has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and the Institut Jean Paoli & Irene Calmettes. Her experience in these institutions has allowed her to contribute to groundbreaking research in the medical field.
Collaborations
Julie has collaborated with notable colleagues, including Daniel Olive and Christine Pasero. These partnerships have further enriched her research and development efforts.
Conclusion
Julie Gertner-Dardenne is a trailblazer in the field of therapeutic antagonists, with a focus on enhancing T cell proliferation. Her innovative work and collaborations continue to impact the medical research landscape.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile